This HTML5 document contains 79 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n15http://www.rxlist.com/cgi/generic3/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01161/identifier/national-drug-code-directory/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n22http://linked.opendata.cz/resource/drugbank/company/
n11http://linked.opendata.cz/resource/mesh/concept/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01161/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01161/identifier/chebi/
n17http://bio2rdf.org/drugbank:
n28http://linked.opendata.cz/resource/drugbank/drug/DB01161/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB01161/identifier/pharmgkb/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01161/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01161/identifier/pubchem-substance/
n5http://linked.opendata.cz/resource/drugbank/property/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01161/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB01161/identifier/drugbank/
n16http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01161
rdf:type
n3:Drug
n3:description
Chloroprocaine hydrochloride is a local anesthetic given by injection during surgical procedures and labor and delivery. Chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential.
n3:dosage
n7:271B4BDE-363D-11E5-9242-09173F13E4C5 n7:271B4BDF-363D-11E5-9242-09173F13E4C5 n7:271B4BE0-363D-11E5-9242-09173F13E4C5 n7:271B4BE1-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
21 +/- 2 seconds
n3:indication
For the production of local anesthesia by infiltration and peripheral nerve block. They are not to be used for lumbar or caudal epidural anesthesia.
owl:sameAs
n13:DB01161 n17:DB01161
dcterms:title
Chloroprocaine
adms:identifier
n19:46508245 n20:PA448946 n21:8612 n23:D00732 n24:0409-4169-01 n25:DB01161 n26:3636 n27:8293 n28:Chloroprocaine
n3:mechanismOfAction
Chloroprocaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. It is hypothesized that Chloroprocaine binds or antagonizes the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.
n3:packager
n22:271B4BD4-363D-11E5-9242-09173F13E4C5 n22:271B4BD5-363D-11E5-9242-09173F13E4C5 n22:271B4BD6-363D-11E5-9242-09173F13E4C5 n22:271B4BD7-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Chloroprocaine is rapidly metabolized in plasma by hydrolysis of the ester linkage by pseudocholinesterase. Urinary excretion is affected by urinary perfusion and factors affecting urinary pH.
n3:synonym
Chloroprocaine Chlorprocaine Cloroprocaina Chloroprocainum 2-Chloroprocaine 4-amino-2-Chlorobenzoic acid 2-(diethylamino)ethyl ester Chloroprocain
n3:toxicity
In mice, the intravenous LD<sub>50</sub> of chloroprocaine HCl is 97 mg/kg and the subcutaneous LD<sub>50</sub> of chloroprocaine HCl is 950 mg/kg.
n8:hasAHFSCode
n9:72-00-00
n3:salt
n3:synthesisReference
Marks, H.C. and Rubin, M.I.; US. Patent 2,460,139; January 25,1949; assigned to Wallace & Tiernan Products, Inc.
n10:hasConcept
n11:M0045735
foaf:page
n15:chloroprocaine.htm
n3:IUPAC-Name
n5:271B4BE6-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4BEC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4BEB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4BE8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4BE9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4BEA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4BFB-363D-11E5-9242-09173F13E4C5 n5:271B4BE4-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4BE2-363D-11E5-9242-09173F13E4C5 n5:271B4BFD-363D-11E5-9242-09173F13E4C5 n5:271B4BE5-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4BE3-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n16:N01BA04
n3:H-Bond-Acceptor-Count
n5:271B4BF2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4BF3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4BED-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4BEE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4BF0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4BEF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4BF1-363D-11E5-9242-09173F13E4C5
n3:absorption
The rate of systemic absorption of local anesthetic drugs is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic injection.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
133-16-4
n3:category
n3:containedIn
n4:271B4BDD-363D-11E5-9242-09173F13E4C5 n4:271B4BD8-363D-11E5-9242-09173F13E4C5 n4:271B4BDB-363D-11E5-9242-09173F13E4C5 n4:271B4BDC-363D-11E5-9242-09173F13E4C5 n4:271B4BD9-363D-11E5-9242-09173F13E4C5 n4:271B4BDA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4BF7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4BF9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4BFA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4BFC-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4BF6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4BF5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4BF8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4BE7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4BF4-363D-11E5-9242-09173F13E4C5